二、监事会会议审议情况 1、审议通过《公司 2024 年年度报告及其摘要》 监事会认为：董事会编制和审议公司 2024 年年度报告的程序符合法律、行 政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的 实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 采纳科技股份有限公司(以下简称"公司")第三届监事会第十二次会议通 知于2025年4月11日以邮件、电话等方式向各位监事发出。会议于2025年4月23 日以现场表决方式，在江苏省江阴市祝塘镇环西路23号采纳医疗办公楼一楼会 议室召开。本次会议由公司监事会主席沈开先生主持，会议应出席监事3人，实 际出席监事3人，公司董事会秘书列席了会议。本次会议的召集、召开及表决符 合《中华人民共和国公司法》等有关法律、法规、规范性文件和《公司章程》 的规定。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 具体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的 《2024 年年度报告》、《2024 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-035 采纳科技股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 采纳科技股份有限公司（以下简称"公司"）第三届董事会第十三次会议通 知于 2025 年 4 月 11 日以邮件、电话等方式向各位董事发出，会议于 2025 年 4 月 23 日以现场会议结合通讯形式，在江苏省江阴市祝塘镇环西路 23 号采纳医疗 办公楼一楼会议室召开。本次会议由公司董事长陆军先生主持，会议应出席董事 9 人，实际出席董事 9 人（其中以通讯表决方式出席会议的董事人数 1 人：侯鹏 先生），公司全体监事、高级管理人员列席了会议。本次会议的召集、召开及表 决符合《中华人民共和国公司法》等有关法律、法规、规范性文件和《公司章程》 的规定。 二、董事会会议审议情况 具体内容详见公司披露于巨潮资讯网（http://www.cninfo.com.cn）的《2024 年年度报告》、《2024 年年度报告摘要》。 上述议案提交董事会审议前，已经第三届董事会审计委员 ...

证券代码：301122 证券简称：采纳股份 公告编号：2025-026 一、审议程序 采纳科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开了第 三届董事会第十三次会议、第三届监事会第十二次会议，分别审议通过了《关于 2024 年 度 利润 分配预 案 》， 具体 内容 详见 公 司同 日披 露于巨 潮 资讯 网 （http://www.cninfo.com.cn）的《第三届董事会第十三次会议决议公告》，公 告编号：2025-035；《第三届监事会第十二次会议决议公告》，公告编号：2025- 036。 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。 二、利润分配方案基本情况 根据中汇会计师事务所（特殊普通合伙）出具的审计报告，公司 2024 年经 审计合并归属于母公司所有者的净利润为 53,093,764.34 元，其中，母公司实现 的净利润为 38,485,147.17 元。截至 2024 年 12 月 31 日，经审计母公司累计可 供分配利润为155,233,475.49元，合并报表中未分配利润为477,626,549.39元。 遵循回报股东、与股东分享公司经营成果的 ...

采纳科技股份有限公司 2024 年度独立董事述职报告 （独立董事：王尚虎） 本人作为采纳科技股份有限公司（以下简称"公司"）的独立董事，严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件以 及《采纳科技股份有限公司章程》（以下简称"《公司章程》"）《采纳科技股份 有限公司独立董事工作制度》（以下简称"《独立董事工作制度》"）的规定和 要求，勤勉尽责履行独立董事的职责，始终站在独立公正的立场参与公司决策， 充分发挥独立董事的作用，积极促进公司健全内控制度及规范运作，维护公司全 体股东尤其是中小股东的合法利益。现将 2024 年度履行独立董事职责的工作情 况报告如下： 一、独立董事的基本情况 王尚虎，男，1980 年生，中国国籍，无永久境外居留权，本科学历经济法 学专业。曾任连云港市赣榆区公证处公证员、副主任，江阴市公证处公证员、业 务部部长；2016 年 7 月至 2019 年 12 月，任江苏滨江律师事务所律师；2020 年 1 月至 ...

采纳科技股份有限公司 2024 年度独立董事述职报告 （独立董事：夏立扬） 本人作为采纳科技股份有限公司（以下简称"公司"）的独立董事，严格按 照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件以 及《采纳科技股份有限公司章程》（以下简称"《公司章程》"）《采纳科技股份 有限公司独立董事工作制度》（以下简称"《独立董事工作制度》"）的规定和 要求，勤勉尽责履行独立董事的职责，始终站在独立公正的立场参与公司决策， 充分发挥独立董事的作用，积极促进公司健全内控制度及规范运作，维护公司全 体股东尤其是中小股东的合法利益。现将 2024 年度履行独立董事职责的工作情 况报告如下： 一、独立董事的基本情况 夏立扬，男，1967 年生，中国国籍，无永久境外居留权，本科学历计算机 科学与技术专业。2013 年至今，任南京麦奥医疗器械咨询有限公司执行董事； 2020 年 6 月-2024 年 9 月，任浙江伏尔特医疗器械股份有限公司独立董事；2023 年 1 ...

采纳科技股份有限公司 2024 年度独立董事述职报告 （独立董事：刘斌） 本人作为采纳科技股份有限公司（以下简称"公司"）的独立董事， 严格 按照《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司独立董事 管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件 以及《采纳科技股份有限公司章程》（以下简称"《公司章程》"）《采纳科技股 份有限公司独立董事工作制度》（以下简称"《独立董事工作制度》"）的规定 和要求，勤勉尽责履行独立董事的职责，始终站在独立公正的立场参与公司决策， 充分发挥独立董事的作用，积极促进公司健全内控制度及规范运作，维护公司全 体股东尤其是中小股东的合法利益。现将 2024 年度履行独立董事职责的工作情 况报告如下： 一、独立董事的基本情况 刘斌，男，1972 年生，中国国籍，无永久境外居留权，大专学历，注册会 计师、注册税务师、注册资产评估师、注册房地产估价师；中国人民政治协商会 议江阴市第十五届委员会委员、第十六届委员会委员、常委；江阴市第十八届人 大常委会计划和预算审查咨询专家。现 ...

前十大流通股东累计持有： 1297.46万股，累计占流通股比： 29.32% 一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.4300 | 0.9200 | -53.26 | 1.7600 | | 每股净资产（元） | 14.81 | 14.78 | 0.2 | 18.46 | | 每股公积金(元) | 9.63 | 9.63 | 0 | 12.82 | | 每股未分配利润(元) | 3.91 | 3.90 | 0.26 | 4.37 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 3.88 | 4.1 | -5.37 | 4.65 | | 净利润(亿元) | 0.53 | 1.13 | -53.1 | 1.62 | | 净资产收益率(%) | 2.94 | 6.37 | -53.85 | 10.28 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 10派2. ...

Financial Performance - The net profit attributable to shareholders decreased by 52.83% compared to the previous year, primarily due to the impact of FDA import warnings affecting product sales and the provision for impairment of inventory and receivables [4]. - The company's operating revenue for 2024 was ¥387,893,051.46, a decrease of 5.50% compared to ¥410,470,639.42 in 2023 [18]. - Net profit attributable to shareholders for 2024 was ¥53,093,764.34, down 52.83% from ¥112,564,144.08 in 2023 [18]. - The basic earnings per share for 2024 was ¥0.43, reflecting a decline of 53.26% from ¥0.92 in 2023 [18]. - The company reported a significant drop in net profit after deducting non-recurring gains and losses, which was ¥32,075,608.69 in 2024, down 62.20% from ¥84,858,023.76 in 2023 [18]. - Revenue from the medical device segment was 198.72 million yuan, a decline of 23.56%, accounting for 51.23% of total revenue [61]. - The animal device segment saw revenue increase to 151.39 million yuan, up 20.83%, representing 39.03% of total revenue [61]. - Laboratory consumables revenue surged to 29.54 million yuan, a growth of 66.08%, making up 7.61% of total revenue [61]. Risk Management - There are no significant risks to the company's ongoing operations, and the medical device industry does not face issues such as overcapacity or continuous decline [4]. - The company has outlined potential risk factors and countermeasures in the management discussion and analysis section of the report [4]. - Future development outlooks and forward-looking statements do not constitute substantive commitments to investors, emphasizing the need for rational investment and risk awareness [4]. - The company emphasizes the importance of investor attention to the outlined risk factors and strategies for future development [4]. - The company faces risks related to customer concentration, with the top five clients accounting for a significant portion of revenue, necessitating diversification strategies [118]. - The company is also aware of foreign exchange risks due to its export-oriented sales, primarily denominated in USD, and plans to implement measures to mitigate these risks [120]. Research and Development - The company continues to focus on research and development of new products and technologies, although specific details were not disclosed in the report [4]. - The company has a dedicated R&D team focused on innovation, with established research centers for veterinary puncture instruments and safety syringes [51][52]. - R&D expenses rose by 23.13% year-on-year to CNY 26,394,205.40, reflecting ongoing investment in product development [72]. - R&D investment reached ¥26,394,205.40 in 2024, up from ¥21,436,278.35 in 2023, marking a year-over-year increase of 23.5% [75]. - The company has developed a range of safety products, including "safety insulin syringes" and "safety blood collection needles," aligning with market trends towards safer medical devices [55]. - The company is developing an automated sheath injector to reduce labor costs and improve production efficiency [71]. - The company has completed the development of a precision urine collector, which enhances measurement accuracy for clinical diagnostics [73]. - The company is working on a safety self-destroying indwelling needle to minimize the risk of blood exposure and infection [73]. Market Expansion and Strategy - The company is actively exploring market expansion opportunities and potential mergers and acquisitions to enhance its competitive position [4]. - The company is actively expanding its overseas factory construction and entering emerging markets to mitigate the impact of U.S. tariffs [59]. - The company plans to enhance product R&D efforts to develop high-value products and improve risk resilience [59]. - The company aims to strengthen its market position in high-safety and high-value products while actively expanding its market share [35]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million yuan for potential deals [157]. Corporate Governance - The company has established a comprehensive governance structure, ensuring compliance with relevant laws and regulations, and maintaining effective communication with shareholders through various channels [128]. - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure and adherence to regulatory requirements [130]. - The company has a structured governance framework including a shareholders' meeting, board of directors, and supervisory board, ensuring operational independence [139]. - The company has established a remuneration and assessment committee in compliance with relevant laws and regulations [160]. - The company has implemented a "Quality Return Dual Improvement" action plan to enhance product quality and customer satisfaction, although specific details on its disclosure were not provided [126]. Employee and Talent Management - The company has a competitive salary policy, combining base salary and performance-based pay, ensuring compliance with national labor laws [177]. - The company emphasizes talent development through targeted training programs and internal cultural enrichment to enhance employee skills and engagement [178]. - The total number of employees at the end of the reporting period is 783, with 499 in production, 138 in technical roles, and 110 in administration [176]. - The total number of employees with a bachelor's degree or above is 105, indicating a focus on educational qualifications within the workforce [176]. - The company has established a long-term incentive mechanism for core employees through indirect shareholding arrangements [185]. Financial Management - The company reported a total investment of 109,726.24 million RMB for the year 2022, with 20,000 million RMB allocated for liquidity support [104]. - The company has committed to using the raised funds for promised investment projects without any significant violations [101]. - The company has not reported any issues or other circumstances regarding the use and disclosure of raised funds [105]. - The company has a clear exit mechanism for employees who leave under specific circumstances, ensuring the protection of company interests [190]. - The internal control audit report indicates that the company maintained effective financial reporting internal controls as of December 31, 2024, in all material respects [198].

Financial Performance - The company's operating revenue for Q1 2025 was ¥72,709,290.01, a decrease of 34.28% compared to ¥110,633,038.63 in the same period last year[5] - Net profit attributable to shareholders was ¥7,680,170.44, down 69.34% from ¥25,045,442.29 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥3,751,442.88, reflecting a decline of 78.81% compared to ¥17,703,983.31 in the previous year[5] - Basic and diluted earnings per share were both ¥0.06, a decrease of 70.00% from ¥0.20 in the same period last year[5] - Operating profit for the current period was ¥8,771,668.48, down 70.4% from ¥29,566,811.75 in the previous period[26] - Net profit for the current period was ¥7,263,799.94, a decline of 70.0% compared to ¥25,045,442.29 in the previous period[26] - Total comprehensive income attributable to the parent company was 7,676,341.95, compared to 25,045,442.29 in the previous period[27] Cash Flow and Assets - The net cash flow from operating activities decreased by 40.24%, amounting to ¥24,974,256.66, down from ¥41,790,114.16 in the previous year[11] - The company's cash and cash equivalents decreased to ¥323,052,115.34 from ¥331,714,012.93, a reduction of 2.0%[21] - Total current assets decreased to ¥1,025,083,767.94 from ¥1,134,334,117.19, a decline of 9.6%[21] - Total non-current assets increased to ¥944,403,424.89 from ¥846,590,930.24, an increase of 11.5%[22] - Total liabilities decreased to ¥147,823,364.57 from ¥166,483,138.90, a reduction of 11.1%[23] - Total equity increased to ¥1,821,663,828.26 from ¥1,814,441,908.53, an increase of 0.1%[23] - Cash inflow from investment activities totaled 608,289,255.61, compared to 317,427,371.11 in the previous period, indicating a significant increase[30] - Cash flow from operating activities decreased by 15% year-over-year[29] - The company’s total cash outflow from operating activities was 83,163,457.06, slightly down from 85,841,219.67 in the previous period[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 6,731[14] - The largest shareholder, Lu Jun, holds 28.29% of shares, totaling 34,580,000 shares, with 25,935,000 shares pledged[14] - The second-largest shareholder, Lu Weiwei, holds 16.16% of shares, totaling 19,760,000 shares[14] - The top ten shareholders collectively hold significant stakes, with the top three shareholders alone accounting for over 50% of total shares[14] - The company has not disclosed any other significant shareholder relationships or actions that may affect shareholding dynamics[15] - The company is under high executive lock-up restrictions, with all major shareholders' shares subject to lock-up during their tenure[17] Operational Challenges - The company is currently facing an FDA import warning affecting its subsidiary, Jiangsu Caina Medical Technology Co., which may significantly impact future revenue and profits[19] - The company is actively communicating with the FDA to resolve the import warning issue, but the timeline for resolution remains uncertain[19] - The company emphasizes the importance of investor awareness regarding potential risks associated with the FDA warning[19] Other Financial Metrics - Total operating costs decreased to ¥69,274,853.76 from ¥79,627,515.63, reflecting a reduction of 13.0%[25] - Investment income decreased by 59.70% to ¥2,128,789.69, down from ¥5,281,918.63 in the previous year due to reduced interest from redeemed financial products[10] - The company experienced a 97.54% reduction in asset impairment losses, reporting a loss of ¥291,950.27 compared to a loss of ¥11,871,141.16 in the previous year, primarily due to prior year provisions related to FDA issues[10] - The company incurred a foreign currency translation loss of -3,828.49[27]

证券代码：301122 证券简称：采纳股份 公告编号：2025-029 采纳科技股份有限公司 关于 2025 年度公司董事、监事及高级管理人员 薪酬方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召开了第 三届董事会第十三次会议、第三届监事会第十二次会议，分别审议通过了《关于 2025 年度公司董事薪酬方案的议案》《关于 2025 年度公司高级管理人员薪酬方 案的议案》《关于 2025 年度公司监事薪酬方案的议案》，其中董事、监事的薪 酬方案尚需提交公司年度股东大会审议。具体薪酬方案如下： 独立董事薪酬为 7 万/年（含税）。 2、监事薪酬方案 在公司担任其他职务的监事，按照其在公司担任的其他职务，依据公司相关 薪酬标准与绩效考核领取薪酬，不单独发放监事津贴，未在公司担任其他职务的 监事，不在公司领取薪酬、监事津贴。 3、高级管理人员薪酬方案 高级管理人员按照其在公司担任的具体事务、实际工作绩效并结合公司经 营业绩等综合评定薪酬。 1 / 2 一、薪酬方案情况 结合公司实际经 ...